Search - tctmd.com

Displaying 641 - 660 of 799

Sort: Relevancy | Date

News Daily News

USPSTF Upholds Stance Against Hormone Therapy to Prevent Chronic Diseases in Menopausal Women

Caitlin E. Cox

December 12, 2017

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

News Conference News AHA 2017

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Michael O'Riordan

November 17, 2017

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Todd Neale

November 14, 2017

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

News Daily News

PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers

Yael L. Maxwell

October 30, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2017

Shelley Wood

October 29, 2017

News Daily News

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Michael O'Riordan

October 26, 2017

News Daily News

Statins and Diabetes: Causal Link Reinforced in New Analysis

Michael O'Riordan

October 25, 2017

News Daily News

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Michael O'Riordan

October 20, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

News Daily News

DOACs Not Associated With Major Bleeding, Mortality: Observational Analysis

Michael O'Riordan

October 19, 2017

News Daily News

NOAC Bleeding Risk Rises With Several Drug Combinations

Michael O'Riordan

October 06, 2017

News Daily News

Generic ARBs Linked to Increased Adverse Events

Michael O'Riordan

October 04, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2017

Shelley Wood

September 30, 2017

News Daily News

‘J-Curve’ in Hypertension May Be Explained by Differences in Patient Characteristics

Todd Neale

September 26, 2017

News Daily News

Acute MI Patients With Cancer History Less Likely to Get Evidence-Based Therapies

L.A. McKeown

September 25, 2017

News Daily News

Quitting Chronic, Low-Dose Aspirin May Boost Risk of Cardiovascular Events

Todd Neale

September 25, 2017

Advertisement

USPSTF Upholds Stance Against Hormone Therapy to Prevent Chronic Diseases in Menopausal Women

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers

TCTMD’s Top 10 Most Popular Stories for October 2017

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Statins and Diabetes: Causal Link Reinforced in New Analysis

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

DOACs Not Associated With Major Bleeding, Mortality: Observational Analysis

NOAC Bleeding Risk Rises With Several Drug Combinations

Generic ARBs Linked to Increased Adverse Events

TCTMD’s Top 10 Most Popular Stories for September 2017

‘J-Curve’ in Hypertension May Be Explained by Differences in Patient Characteristics

Acute MI Patients With Cancer History Less Likely to Get Evidence-Based Therapies

Quitting Chronic, Low-Dose Aspirin May Boost Risk of Cardiovascular Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content